TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36852107

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus velpatasvir (SOF/VEL) 400/100 mg once daily for 8 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus velpatasvir (SOF/VEL)
Number of subjects: 20
Study: 36852452

Group type: EXPERIMENTAL
Intervention: High PD-L1 expression by tumor cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low PD-L1 expression
Number of subjects: 0

Group type: COMPARATOR
Intervention: High PD-L1 levels
Number of subjects: 0
Study: 36852670

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36852705

Group type: EXPERIMENTAL
Intervention: Linerixibat 40 mg BID
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Linerixibat (various doses)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Linerixibat
Number of subjects: 147
Study: 36852723

Group type: EXPERIMENTAL
Intervention: Monalizumab (22.5-750 mg or 10 mg/kg every 2 weeks)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Monalizumab
Number of subjects: 507
Study: 36852998

Group type: EXPERIMENTAL
Intervention: COVID-HIGIV 100 mg/kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: COVID-HIGIV 200 mg/kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: COVID-HIGIV 400 mg/kg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 36853224

Group type: COMPARATOR
Intervention: Prednisone for 14 to 28 days at presentation of IgAV
Number of subjects: 1963

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1963

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 1963

Group type: COMPARATOR
Intervention: Intravenous (IV) cyclophosphamide
Number of subjects: 1963

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 1963

Group type: COMPARATOR
Intervention: Antiplatelet therapy
Number of subjects: 1963

Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 1963

Group type: COMPARATOR
Intervention: MMF
Number of subjects: 1963
Study: 36853250

Group type: EXPERIMENTAL
Intervention: Ultrasound renal denervation
Number of subjects: 224

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 224
Study: 36853388

Group type: EXPERIMENTAL
Intervention: NIR (near-infrared autofluorescence) group
Number of subjects: 147

Group type: COMPARATOR
Intervention: NONIR (standard care) group
Number of subjects: 147
Study: 36853598

Group type: EXPERIMENTAL
Intervention: UT-DSAEK
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: DMEK
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cataract surgery
Number of subjects: 72
Study: 36853611

Group type: EXPERIMENTAL
Intervention: Combined drug approach with standard of care (static cold storage)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard of care only (control group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combined drug approach
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 36853612

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (1.5 g), thiamine hydrochloride (100 mg), and hydrocortisone sodium succinate (50 mg) every 6 hours for 96 hours
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C, thiamine, and hydrocortisone
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 36853627

Group type: EXPERIMENTAL
Intervention: Ultrasound renal denervation (uRDN)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 506
Study: 36853719

Group type: EXPERIMENTAL
Intervention: Single-nuclei RNA-Seq
Number of subjects: 0
Study: 36853754

Group type: EXPERIMENTAL
Intervention: Severe Suicidal Ideation (SI)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Severe SI
Number of subjects: 249
Study: 36853800

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 36854054

Group type: EXPERIMENTAL
Intervention: Stool CMV-PCR
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Plasma CMV-PCR
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Either positive plasma or positive stool CMV-PCR
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both positive stool and plasma CMV-PCR
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Stool CMV-PCR and Plasma CMV-PCR correlation
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Stool CMV-PCR correlation with cytomegalic cell count
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Plasma CMV-PCR correlation with cytomegalic cell count
Number of subjects: 117

Group type: COMPARATOR
Intervention: Volunteers
Number of subjects: 117
Study: 36854071

Group type: EXPERIMENTAL
Intervention: Dinutuximab beta (DB) plus subcutaneous interleukin-2 (scIL2) after haplo-SCT
Number of subjects: 68
Study: 36854097

Group type: EXPERIMENTAL
Intervention: Novel tests including blood, urine, and stool collection for TB diagnosis
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Standard assessments including TB signs and symptoms, TB history, radiography, tuberculin skin test, HIV testing, and spirometry
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Reference standard testing (culture, Xpert Ultra) using respiratory samples (sputum, gastric aspirate, nasopharyngeal aspirate)
Number of subjects: 1000
Study: 36854112

Group type: EXPERIMENTAL
Intervention: Concussion-related return to the ED within 3 months
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Concussion-related return to the ED within 14 days
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: History of migraines
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Headache as a symptom on revisit
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Return rate by gender and age
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Risk scores in prognostication
Number of subjects: 632
Study: 36854366

Group type: EXPERIMENTAL
Intervention: High Intent
Number of subjects: 2406

Group type: COMPARATOR
Intervention: Already Vaccinated
Number of subjects: 2406
Study: 36854456

Group type: EXPERIMENTAL
Intervention: Perceived workplace support (assessed via self-reported level on a single-item Likert scale)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in perceived workplace support
Number of subjects: 0
Study: 36854566

Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 31
Study: 36854570

Group type: EXPERIMENTAL
Intervention: Bispecific antibody (bsAb)-KN046
Number of subjects: 18
Study: 36854583

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy for 12 weeks
Number of subjects: 174

Group type: COMPARATOR
Intervention: Digital self-care intervention for 12 weeks
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis at 1-year follow-up
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Primary outcome measure (Patient-oriented Eczema Measure)
Number of subjects: 174
Study: 36854592

Group type: EXPERIMENTAL
Intervention: Viborg Screening Programme (VISP)
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Control group (surrounding municipalities)
Number of subjects: 1100
Study: 36854596

Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 130

Group type: COMPARATOR
Intervention: No surgical mask
Number of subjects: 130
Study: 36854601

Group type: EXPERIMENTAL
Intervention: Restrictive protocol for non-resuscitation fluids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 36854604

Group type: EXPERIMENTAL
Intervention: Afatinib combined with GEMOX chemotherapy (gemcitabine and oxaliplatin)
Number of subjects: 0
Study: 36854798

Group type: EXPERIMENTAL
Intervention: Iron-oxide-impregnated polyvinylidene fluoride (PVDF) mesh
Number of subjects: 20
Study: 36854863

Group type: EXPERIMENTAL
Intervention: Novel methodology for direct co-registration of autoradiographs and histopathology
Number of subjects: 5
Study: 36854893

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 3420

Group type: COMPARATOR
Intervention: No diabetes mellitus
Number of subjects: 3420
Study: 36854916

Group type: EXPERIMENTAL
Intervention: Identified biomarkers for SIDD (n=13)
Number of subjects: 7017

Group type: EXPERIMENTAL
Intervention: Identified biomarkers for SIRD (n=2)
Number of subjects: 7017

Group type: EXPERIMENTAL
Intervention: Identified biomarkers for MOD (n=7)
Number of subjects: 7017

Group type: EXPERIMENTAL
Intervention: Identified biomarkers for MARD (n=11)
Number of subjects: 7017
Study: 36855020

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 855
Study: 36855089

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Morphine-based analgesia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Piritramide-based analgesia
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 36855099

Group type: EXPERIMENTAL
Intervention: Tafolecimab 150 mg Q2W
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Tafolecimab 450 mg Q4W
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo Q2W
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo Q4W
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Tafolecimab (both doses)
Number of subjects: 149
Study: 36855109

Group type: EXPERIMENTAL
Intervention: 300,000 IU cholecalciferol followed by 1400 IU cholecalciferol + 500 mg of calcium daily (n = 151)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo (n = 156)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 307
Study: 36855155

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 280

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 280
Study: 36855160

Group type: EXPERIMENTAL
Intervention: High-dose intravenous ketamine infusions
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 36855169

Group type: EXPERIMENTAL
Intervention: Wangbi granule 12.0 g, three times a day for 12 weeks
Number of subjects: 340

Group type: COMPARATOR
Intervention: Wangbi placebo 12.0 g, three times a day for 12 weeks
Number of subjects: 340
Study: 36855177

Group type: EXPERIMENTAL
Intervention: estradiol treatment for 3 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo treatment for 3 weeks
Number of subjects: 100
Study: 36855194

Group type: EXPERIMENTAL
Intervention: HOLA health promotion intervention (community health worker-led, multicomponent intervention including social and physical activation session, group walk for 45 min, 3×/week for 16 weeks)
Number of subjects: 18
Study: 36855202

Group type: EXPERIMENTAL
Intervention: Eustachian tube dilation using an endovascular balloon
Number of subjects: 12
Study: 36855211

Group type: EXPERIMENTAL
Intervention: Single-step StreamLight® TE-PRK using EX500 excimer laser (Alcon Laboratories, USA)
Number of subjects: 30
Study: 36855214

Group type: EXPERIMENTAL
Intervention: Group-based dance intervention (8-week, 3 times/week)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 36855328

Group type: EXPERIMENTAL
Intervention: Pictorial-based risk communication intervention
Number of subjects: 14
Study: 36855334

Group type: EXPERIMENTAL
Intervention: Fabric-Based Wireless Electroceutical Dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-Care Treatment
Number of subjects: 0
Study: 36855737

Group type: EXPERIMENTAL
Intervention: Endotracheal Intubation
Number of subjects: 142
Study: 36855931

Group type: EXPERIMENTAL
Intervention: Mild group (DS < 50%)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Intermediate group (DS 50%-70%)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Severe group (DS > 70%)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Angio-FFR ≤ 0.8
Number of subjects: 480
Study: 36856064

Group type: EXPERIMENTAL
Intervention: Bilateral high-frequency noninvasive peroneal nerve stimulation (NPNS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 20
Study: 36856104

Group type: EXPERIMENTAL
Intervention: Kabat Motor Control Re-education
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physical therapy selected designed program (Control)
Number of subjects: 30
Study: 36856122

Group type: EXPERIMENTAL
Intervention: Oral intake of fermented milk
Number of subjects: 0
Study: 36856135

Group type: EXPERIMENTAL
Intervention: Hypothetical polygenic risk scores for alcohol use disorder
Number of subjects: 325
Study: 36856258

Group type: EXPERIMENTAL
Intervention: Paper version of the Integrated Palliative Care Outcome Scale (IPOS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Electronic version of the Integrated Palliative Care Outcome Scale (eIPOS)
Number of subjects: 50
Study: 36856280

Group type: EXPERIMENTAL
Intervention: Quadrupled semitendinosus tendon (ST) graft
Number of subjects: 162

Group type: COMPARATOR
Intervention: Doubled semitendinosus and gracilis tendon (ST/G) graft
Number of subjects: 162
Study: 36856456

Group type: COMPARATOR
Intervention: Novel Dietary Supplement
Number of subjects: 0
Study: 36856614

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg once daily
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg once daily
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 416
Study: 36856617

Group type: EXPERIMENTAL
Intervention: Neoadjuvant-adjuvant pembrolizumab (3 doses before surgery and 15 doses after surgery)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Adjuvant-only pembrolizumab (200 mg intravenously every 3 weeks for a total of 18 doses)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Neoadjuvant-adjuvant pembrolizumab
Number of subjects: 313

Group type: COMPARATOR
Intervention: Adjuvant-only pembrolizumab
Number of subjects: 313
Study: 36856701

Group type: EXPERIMENTAL
Intervention: Memantine (10-20 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 36856733

Group type: EXPERIMENTAL
Intervention: Temozolomide (first-line chemotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (second-line treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors and everolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peptide receptor radionuclide therapy
Number of subjects: 0
Study: 36856748

Group type: EXPERIMENTAL
Intervention: No drainage after elective day-case laparoscopic cholecystectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Drainage after elective day-case laparoscopic cholecystectomy
Number of subjects: 200
Study: 36856835

Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage
Number of subjects: 209

Group type: COMPARATOR
Intervention: Resection
Number of subjects: 209
Study: 36856848

Group type: EXPERIMENTAL
Intervention: ProTaper Universal Retreatment (PTUR)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Reciproc Blue (RB)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: D-Race (DR) + XP-Endo Finisher R (XPFR)
Number of subjects: 75
Study: 36856866

Group type: EXPERIMENTAL
Intervention: APOE-ε4 carriers with positive Aβ PET VR in temporal areas (n=19, 9.81%)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: APOE-ε4 carriers with positive Aβ PET VR in the striatum (n=8, 4.14%)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: APOE-ε4 carriers with positive Aβ PET VR in temporal and parietal regions, and in the striatum
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: APOE-ε4 carriers (general)
Number of subjects: 352
Study: 36856877

Group type: EXPERIMENTAL
Intervention: PGE1 treatment
Number of subjects: 22
Study: 36856978

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine-A (CsA) 0.1% cationic emulsion (Ikervis) instilled once daily to both eyes from 3-5 weeks pre-HSCT to 12 months post-HSCT
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine-A (CsA) 0.1% cationic emulsion (Ikervis)
Number of subjects: 19
Study: 36857035

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 14565

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14565
Study: 36857053

Group type: EXPERIMENTAL
Intervention: Intensive BP treatment (SBP target <120 mm Hg)
Number of subjects: 670
Study: 36857058

Group type: EXPERIMENTAL
Intervention: Autologous fat transfer (AFT)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Implant-based reconstruction (IBR)
Number of subjects: 193
Study: 36857103

Group type: EXPERIMENTAL
Intervention: Age at diagnosis <6 years
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Age at diagnosis <2 years
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Posterior hypothalamic involvement and hypothalamic lesion (HL)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Age at diagnosis
Number of subjects: 709
Study: 36857318

Group type: EXPERIMENTAL
Intervention: 4S-AF scheme
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: 3S-AF scheme (excluding symptoms domain)
Number of subjects: 341
Study: 36857330

Group type: EXPERIMENTAL
Intervention: Digital meditation (MED)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Digital meditation + healthy eating (MED+HE)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Active control (HE)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Digital meditation (MED) for those high in binge eating
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Digital meditation + healthy eating (MED+HE) for those high in binge eating
Number of subjects: 161
Study: 36857339

Group type: EXPERIMENTAL
Intervention: RELiZORB enzyme cartridge used daily with enteral nutrition (EN) for 90 days
Number of subjects: 0
Study: 36857393

Group type: EXPERIMENTAL
Intervention: ATG 4.5 mg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: ATG 6.0 mg/kg
Number of subjects: 36
Study: 36857477

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Semaglutide 1 mg
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 36857519

Group type: EXPERIMENTAL
Intervention: Acute myocardial infarction (AMI) patients
Number of subjects: 2705

Group type: EXPERIMENTAL
Intervention: Combined phenotype of 'MA ≥ 68 mm' and 'LY30 < 0.2%' in AMI patients
Number of subjects: 2705

Group type: COMPARATOR
Intervention: Non-AMI patients
Number of subjects: 2705
Study: 36857596

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2045

Group type: EXPERIMENTAL
Intervention: Metformin + Aspirin
Number of subjects: 2045

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2045
Study: 36857740

Group type: EXPERIMENTAL
Intervention: Lacto-ovo-vegetarians (LOV)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-vegetarians (NV)
Number of subjects: 64
Study: 36857956

Group type: EXPERIMENTAL
Intervention: Rapidly cleaved saccharose (SAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slowly cleaved isomaltulose (ISO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test meals containing saccharose or isomaltulose with milk protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Casein
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endogenous incretins
Number of subjects: 0
Study: 36857962

Group type: EXPERIMENTAL
Intervention: 60 days of bed rest
Number of subjects: 20
Study: 36857997

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 5500
Study: 36858257

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 0.03 mcg/kg/min
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 0.02 mcg/kg/min
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 0.01 mcg/kg/min
Number of subjects: 271

Group type: COMPARATOR
Intervention: Epinephrine infusion (all doses)
Number of subjects: 271
Study: 36858265

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 8 weeks
Number of subjects: 159

Group type: COMPARATOR
Intervention: Normal controls (NCs)
Number of subjects: 159
Study: 36858270

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 42
Study: 36858602

Group type: EXPERIMENTAL
Intervention: CADScorSystem (ultrasensitive microphone for diastolic heart sound analysis)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Serial high-sensitive troponin T measurements
Number of subjects: 167
Study: 36858662

Group type: EXPERIMENTAL
Intervention: Self-expanding transcatheter heart valves (THVs)
Number of subjects: 723

Group type: COMPARATOR
Intervention: Balloon-expandable transcatheter heart valves (THVs)
Number of subjects: 723
Study: 36858721

Group type: EXPERIMENTAL
Intervention: Lenvatinib (20 mg per day orally in 21-day cycles) plus pembrolizumab (200 mg intravenously every 21 days)
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Sunitinib (50 mg per day orally, 4 weeks on and 2 weeks off)
Number of subjects: 1069
Study: 36858722

Group type: EXPERIMENTAL
Intervention: OEPA (vincristine 1·5 mg/m², etoposide, prednisone, and doxorubicin) without radiotherapy
Number of subjects: 713

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 713
Study: 36858723

Group type: EXPERIMENTAL
Intervention: Adjuvant paclitaxel and trastuzumab
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: HER2DX risk score
Number of subjects: 406
Study: 36858756

Group type: EXPERIMENTAL
Intervention: Therapist-Assisted Self-Help Internet-Based Intervention (online CBT intervention)
Number of subjects: 136
Study: 36858765

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Seasonal Affective Disorder (CBT-SAD)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Light Therapy
Number of subjects: 174
Study: 36858787

Group type: EXPERIMENTAL
Intervention: Allogeneic CD7-CAR T cells
Number of subjects: 0
Study: 36859250

Group type: EXPERIMENTAL
Intervention: 'Have a Say' programme (dyadic advance care planning intervention)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36